Layered lipid microcapsules for mesalazine delayed-release in children

International Journal of Pharmaceutics

Volumn 421, Issue 2, 2011, Pages 293-300

  Balducci, Anna Giulia ^a   Colombo, Gaia ^b   Corace, Giuseppe ^c   Cavallari, Cristina ^c   Rodriguez, Lorenzo ^c   Buttini, Francesca ^a   Colombo, Paolo ^a   Rossi, Alessandra ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Delayed release; Excipient microparticles; Lipid; Mesalazine; Microcapsules; Spray congealing

Indexed keywords

LIPID; MANNITOL; MESALAZINE; PHOSPHATE BUFFERED SALINE; PHOSPHATIDYLCHOLINE; STEARIC ACID;

ARTICLE; DELAYED DRUG RELEASE; HYDROPHILICITY; MICROCAPSULE; PH; PRIORITY JOURNAL; SPRAY DRYING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CALORIMETRY, DIFFERENTIAL SCANNING; CAPSULES; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; LECITHINS; MANNITOL; MESALAMINE; MICROSCOPY, ELECTRON, SCANNING; POLYMETHACRYLIC ACIDS; POWDER DIFFRACTION; STEARIC ACIDS; WAXES; X-RAY DIFFRACTION;

EID: 81755165818     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2011.09.043     Document Type: Article

References (40)

1. B. Albertini, N. Passerini, F. Pattarino, and L. Rodriguez New spray-congealing atomizer for the microencapsulation of highly concentrated solid and liquid substances Eur. J. Pharm. Biopharm. 69 2008 348 357
2. C. Behrens, P. Bias, H. Malchow, and A. Readler Mesalazine (5-ASA) micropellets show comparable efficacy and tolerability as mesalazine tablets in patients with ulcerative colitis a prospective, multinational, randomised, double-blind, active-controlled clinical phase II study Gastroenterology 124 2003 A379
3. R. Bergman, and M. Parkes Systematic review: the use of mesalazine in inflammatory bowel disease Aliment. Pharm. Ther. 23 2006 841 855
4. J. Breitkreutz, and J. Boos Paediatric and geriatric drug delivery Expert Opin. Drug Deliv. 4 2007 37 45
5. M.J. Carter, A.J. Lobo, and S. Travis Guidelines for the management of inflammatory bowel disease in adults Gut 53 2004 1 16
6. M.K. Chourasia, and S.K. Jain Design and development of multiparticulate system for targeted drug delivery to colon Drug Deliv. 11 2004 201 207
7. G. Di Pretoro, L. Zema, A. Gazzaniga, S.L. Rough, and D.I. Wilson Extrusion-spheronisation of highly loaded 5-ASA dosage forms Int. J. Pharm. 402 2010 153 164
8. T.B. Ernest, D.P. Elder, L.G. Martini, M. Roberts, and J.L. Ford Developing paediatric medicines: identifying the needs and recognizing the challenges J. Pharm. Pharmacol. 59 2007 1043 1055
9. D.R. Friend New oral delivery systems for treatment of inflammatory bowel disease Adv. Drug Deliv. Rev. 57 2005 247 265
10. C. Fude, Y. Lei, J. Jie, P. Hongze, L. Wenhui, and C. Dongmei Preparation and in vitro evaluation of pH, time-based and enzyme-degradable pellets for colonic drug delivery Drug Deliv. Ind. Pharm. 33 2007 999 1007
11. J.P. Gisbert, F. Gomollon, J. Mate, and J.M. Pajares Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review Digest. Dis. Sci. 47 2000 471 488
12. V.K. Gupta, T.E. Beckert, and J.C. Price A novel pH- and time-based multi-unit potential colonic drug delivery system. I. Development Int. J. Pharm. 213 2001 83 91
13. T. Hatch, and S.P. Choate Statistical description of the size properties of non-uniform particulate substances J. Franklin Inst. 207 1929 369 387
14. A. Jain, Y. Gupta, and S. Jain Perspectives of biodegradable natural polysaccharides for site-specific drug delivery to the colon J. Pharm. Pharm. Sci. 10 2007 86 128
15. S.K. Jain, A. Jain, Y. Gupta, A. Jain, P. Kharem, and M. Kannandasan Targeted delivery of 5-ASA to colon using chitosan hydrogel microspheres J. Drug Deliv. Sci. Technol. 18 2008 315 321
16. Y. Jung, H.H. Kim, H. Kim, H. Kong, B. Choi, Y. Yang, and Y. Kim Evaluation of 5-aminosalicyltaurine as a colon-specific prodrug of 5-aminosalicylic acid for treatment of experimental colitis Eur. J. Pharm. Sci. 28 2006 26 33
17. M.A. Kamm, W.J. Sandborn, M. Gassull, S. Schreiber, L. Jackowski, T. Butler, A. Lyne, D. Stephenson, M. Palmen, and R.E. Joseph Once-daily, high-concentration MMX mesalamine in active ulcerative colitis Gastroenterology 132 2007 66 75
18. R. Karagozian, and R. Burakoff The role of mesalamine in the treatment of ulcerative colitis Ther. Clin. Risk Manag. 3 2007 893 903
19. Y. Karrout, C. Neut, D. Wils, F. Siepmann, L. Deremaux, M.P. Flament, L. Dubreuil, P. Desreumaux, and J. Siepmann Novel polymeric film coatings for colon targeting: drug release from coated pellets Eur. J. Pharm. Sci. 37 2009 427 433
20. M.J. Killeen Spray drying and spray congealing of pharmaceutics J. Swarbrick, J.C. Boylan, Encyclopedia of Pharmaceutical Technology 1996 Marcel Dekker Inc. New York 207 221
21. U. Klotz The role of aminosalicylates at the beginning of the new millennium in the treatment of chronic inflammatory bowel disease Eur. J. Clin. Pharmacol. 56 2000 353 362
22. A. Kornbluth, and D. Sachar Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee Am. J. Gastroenterol. 99 2004 1371 1385
23. P.L. Lakatos, S. Fisher, L. Lakatos, I. Gal, and J. Papp Current concept on the pathogenesis of inflammatory bowel disease-crosstalk between genetic and microbial factors: pathogenic bacteria and altered bacterial sensing or changes in mucosal integrity take toll? World J. Gastroenterol. 12 2006 1829 1841
24. K. Mladenovska, R.S. Raicki, E.I. Janevik, T. Ristoski, M.J. Pavlova, Z. Kavrakovski, M.G. Dodov, and K. Goracinova Colon-specific delivery of 5-aminosalicylic acid from chitosan-Ca-alginate microparticles Int. J. Pharm. 342 2007 124 136
25. T. Minko Drug targeting to the colon with lectins and neoglycoconjugates Adv. Drug Deliv. Rev. 56 2004 491 509
26. J. Moore, and H. Flanner Mathematical comparison of curves with an emphasis on in vitro dissolution profiles Pharm. Technol. 20 1996 64 74
27. T. Nunn, and J. Williams Formulation of medicines for children Br. J. Clin. Pharmacol. 59 2005 674 676
28. J. Nunthanid, K. Huanbutta, M. Luangtana-anan, P. Sriamornsak, S. Limmatvapirat, and S. Puttipipatkhachorn Development of time-, pH-, and enzyme-controlled colonic drug delivery using spray-dried chitosan acetate and hydroxypropyl methylcellulose Eur. J. Pharm. Biopharm. 68 2008 253 259
29. N. Passerini, B. Perissutti, B. Albertini, D. Voinovich, M. Moneghini, and L. Rodriguez Controlled release of verapamil hydrochloride from waxy microparticles prepared by spray congealing J. Controlled Release 88 2003 263 275
30. N. Passerini, B. Albertini, B. Perissutti, and L. Rodriguez Evaluation of melt granulation and ultrasonic spray congealing as techniques to enhance the dissolution of praziquantel Int. J. Pharm. 318 2006 92 102
31. A. Qureshi, and R. Cohen Mesalamine delivery systems: do they really make much difference Adv. Drug Deliv. Rev. 57 2005 281 302
32. R.P. Raffin, P. Colombo, F. Sonvico, F.S. Polleto, G. Colombo, A. Rossi, A.R. Pohlmann, and S.S. Guterres Soft agglomerates of pantoprazole gastro-resistant microparticles for oral administration and intestinal release J. Drug Deliv. Sci. Technol. 17 2007 407 413
33. R.P. Raffin, P. Colombo, F. Sonvico, A. Rossi, D.S. Jornada, A.R. Pohlmann, and S.S. Guterres Agglomerates containing pantoprazole microparticles: modulating the drug release AAPS Pharm. Sci. Technol. 10 2009 335 345
34. M. Rodrguez, J.L. Vila-Jato, and D. Torres Design of a new multiparticulate system for potential site-specific and controlled drug delivery to the colonic region J. Controlled Release 55 1998 67 77
35. P. Russo, F. Buttini, F. Sonvico, R. Bettini, G. Massimo, C. Sacchetti, P. Colombo, and P. Santi Chimeral agglomerates of microparticles for administration of caffeine nasal powders J. Drug Deliv. Sci. Technol. 14 2004 449 454
36. P. Russo, C. Sacchetti, I. Pasquali, R. Bettini, G. Massimo, P. Colombo, and A. Rossi Primary microparticles and agglomerates of morphine for nasal insufflation J. Pharm. Sci. 95 2006 2553 2561
37. W.J. Sandborn, J. Regula, B.G. Feagan, E. Belousova, N. Jojic, M. Lukas, B. Yacyshyn, P. Krzeski, C.H. Yeh, C.A. Messer, and S.B. Hanauer Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis Gastroenterology 137 2009 1934 1943
38. W.J. Sandborn, J. Korzenik, B. Lashner, J.A. Leighton, U. Mahadevan, J.F. Marion, M. Safdi, C.A. Sninsky, R.M. Patel, K.A. Friedenberg, P. Dunnmon, D. Ramsey, and S. Kane Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) for maintenance of remission of ulcerative colitis: the QD dosing investigation for efficacy in UC maintenance trial Gastroenterology 138 2010 1286 1296
39. K.P. Steed, G. Hooper, N. Monti, M. Strolin Benedetti, G. Fornasini, and I.R. Wilding The use of pharmacoscintigraphy to focus the development strategy for a novel 5-ASA colon targeting system ("TIME CLOCK" system) J. Controlled Release 49 1997 115 122
40. G. Van den Mooter Colon drug delivery Expert. Opin. Drug Deliv. 3 2006 111 125